Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA:600196)

Market Cap	54.24B -32.5%
Revenue (ttm)	42.59B +6.2%
Net Income	3.39B +4.4%
EPS	1.28 +5.2%
Shares Out	2.64B
PE Ratio	17.21
Forward PE	22.03
Dividend	0.39 (1.77%)
Ex-Dividend Date	Jul 27, 2026

Volume	14,394,191
Open	21.85
Previous Close	21.78
Day's Range	21.81 - 22.16
52-Week Range	20.85 - 32.25
Beta	0.43
Analysts	Buy
Price Target	33.50 (+52.07%)
Earnings Date	Aug 25, 2026

About SHA:600196

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, car...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 40,684
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600196

Financial Performance

In 2025, SHA:600196's revenue was 41.66 billion, an increase of 1.45% compared to the previous year's 41.07 billion. Earnings were 3.37 billion, an increase of 21.69%.

Analyst Summary

According to 6 analysts, the average rating for 600196 stock is "Buy." The 12-month stock price target is ¥33.50, which is an increase of 52.07% from the latest price.

Price Target

¥33.50

(52.07% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 18, 2026

Data Sources Report a data error